April 6, 2023 06:13 AM EDTUpdated 06:25 AM
Peer Review

Af­ter decades in Big Phar­ma, Kel­ly Page heads to 'growth stage'; Al­lied with No­var­tis, Bi­cy­cle se­lects de­vel­op­ment chief

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Nicole DeFeudis

Editor

Fol­low­ing a decades-long ca­reer in Big Phar­ma, Kel­ly Page want­ed to use her re­search and com­mer­cial ex­pe­ri­ence to help a small com­pa­ny grow.

Last Tues­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times